TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells

Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient basis. Understanding cell and molecular mechanisms determining fraction size...

Descripción completa

Detalles Bibliográficos
Autores principales: Anbalagan, Selvakumar, Ström, Cecilia, Downs, Jessica A., Jeggo, Penny A., McBay, David, Wilkins, Anna, Rothkamm, Kai, Harrington, Kevin J., Yarnold, John R., Somaiah, Navita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007815/
https://www.ncbi.nlm.nih.gov/pubmed/33782505
http://dx.doi.org/10.1038/s41598-021-86681-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007815/
https://www.ncbi.nlm.nih.gov/pubmed/33782505
http://dx.doi.org/10.1038/s41598-021-86681-6

Ejemplares similares